Episode Details
Back to EpisodesGLP-1 Coverage: Why Employers Are Dropping Access, and What Comes Next w/ Jay Bregman
Description
Losing access to a GLP-1 can happen even when treatment is working exactly as intended. A lower BMI, an insurance change, or an employer facing open-ended costs can suddenly turn a prescription into a maze of denials, prior authorizations, and unexpected expenses.
In this episode, Ana Reisdorf speaks with Jay Bregman, founder and CEO of Andel, about why traditional insurance struggles to cover high-demand medications and how direct-to-employer purchasing could offer another path. Jay explains how fixed employer contributions can make GLP-1 benefits more predictable, why he believes prior authorizations add unnecessary costs, and what patients can do when their coverage is at risk.
They also discuss Medicare access, losing coverage after successful weight loss, options for self-employed people, compounded medications, future GLP-1 competition, and whether access can become more equitable.
**IN THIS EPISODE**
- Why GLP-1 demand creates problems for traditional insurance
- How pharmaceutical middlemen affect medication pricing and access
- What direct-to-employer purchasing means
- Why employers hesitate to fund open-ended GLP-1 coverage
- How fixed employer contributions could make benefits more sustainable
- Why successful treatment and a lower BMI can lead to lost coverage
- The hidden administrative costs of prior authorizations
- What to do if you’re worried about affording your medication
- Options for self-employed people without employer assistance
- Jay’s perspective on Medicare, compounded medications, competition, and equitable access
**ABOUT THE GUEST**
Jay Bregman is the founder and CEO of Andel, a healthcare technology platform that enables high-cost medications like GLP-1s to be more accessible through employer benefits. With more than two decades of experience building and scaling companies, Jay brings a strong understanding of how policy, pricing, and market incentives intersect.
In developing Andel, he has focused on redesigning access pathways for high-demand, high-cost drugs that traditional coverage models fail to accommodate. His perspective on GLP-1 access and employer responsibility has been featured in Inc., STAT News, and Pharmaceutical Executive. He has also spoken at TEDx and Web Summit about business leadership.
Jay appears in this episode in his capacity as Andel’s founder and CEO. His comments about Andel and the pharmaceutical market reflect his experience and commercial perspective.
**CONNECT WITH JAY**
Andel:
https://www.andel.org/
Andel Raises $4.5M for Its Employer-Supported Medication Marketplace:
https://www.prnewswire.com/news-releases/andel-raises-4-5m-for-its-employer-supported-medication-marketplace-302588465.html
Andel Launches New Direct-to-Employer Medication Platform:
https://www.prnewswire.com/news-releases/andel-launches-new-direct-to-employer-medication-platform-to-make-glp-1s-affordable-for-millions-302709372.html
**SPONSORS**
This episode includes sponsored messages from Johnson Fitness & Wellness and gutzy Organic.
Johnson Fitness & Wellness offers strength-training equipment, cardio machines, recovery products, and expert guidance for a range of fitness levels, spaces, and budgets. Visit https://www.johnsonfitness.com/ and use code GLP1Hub5 for an exclusive offer for GLP-1 Hub listeners.